ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Oncology and Hematology News and Journal Articles

New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer

Zeljka Jutric, MD, and Laleh G. Melstrom, MD, MS
Cancer In this article we will discuss the definitions of resectability, describe the current diagnostic tests for pancreatic cancer, and review strategies for maximizing treatment outcomes in patients with resectable pancreatic cancer.

Recent Content

The primary tumor location was an independent prognostic marker in patients with RAS wild-type metastatic colorectal cancer after multivariable adjustment.

This slide show highlights some of this year’s FDA approvals of cancer treatments, including new therapies and indications for breast cancer, lung cancer, and various blood cancers, as well as the first approval based not on disease site but rather by a tumor marker.

Adding midostaurin to chemotherapy prolonged survival in younger adult patients with acute myeloid leukemia and a FLT3 mutation, according to a randomized trial.

Adding the novel CD20 inhibitor ublituximab to ibrutinib offered improved response rates and greater depth of response over ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia.

An anti–PD-1 monoclonal antibody is safe and effective for patients with unresectable, locally advanced, or metastatic cutaneous squamous cell carcinoma.

Long-term survivors of wild-type KRAS colorectal cancer tumors had significantly improved survival with regular use of nonsteroidal anti-inflammatory drugs.

Adding nintedanib to pemetrexed/cisplatin improved the progression-free survival of patients with malignant pleural mesothelioma compared with placebo.

By clicking Accept, you agree to become a member of the UBM Medica Community.